1,360 reports of this reaction
3.6% of all AMIKACIN reports
#5 most reported adverse reaction
HOSPITALISATION is the #5 most commonly reported adverse reaction for AMIKACIN, manufactured by Insmed Incorporated. There are 1,360 FDA adverse event reports linking AMIKACIN to HOSPITALISATION. This represents approximately 3.6% of all 37,285 adverse event reports for this drug.
Patients taking AMIKACIN who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is moderately reported among AMIKACIN users, representing a notable but not dominant share of adverse events.
In addition to hospitalisation, the following adverse reactions have been reported for AMIKACIN:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1,360 FDA reports for AMIKACIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 3.6% of all adverse event reports for AMIKACIN, making it a notable side effect.
If you experience hospitalisation while taking AMIKACIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.